Printer Friendly

BRISTOL-MYERS SQUIBB ANNOUNCES COURT RULING

 BRISTOL-MYERS SQUIBB ANNOUNCES COURT RULING
 NEW YORK, July 22 /PRNewswire/ -- Bristol-Myers Squibb Company


(NYSE: BMY) announced today that Judge Alfred M. Wolin of the United States District Court for the District of New Jersey has ruled that the sale of Zenith Laboratories' cefadroxil DC would constitute an act of infringement of Bristol-Myers Squibb's patent on crystalline cefadroxil monohydrate. In his ruling, Judge Wolin indicated that Zenith will not be permitted to market cefadroxil DC until after the expiration of Bristol-Myers Squibb's patent which does not occur until March 12, 2002. Cefadroxil DC from Zenith Laboratories is not currently marketed in the United States.
 Bristol-Myers Squibb markets cefadroxil monohydrate under the trademark Duricef.
 -0- 7/22/92
 /CONTACT: Jon Weisberg of Bristol-Myers Squibb, 212-546-4343/
 (BMY) CO: Bristol-Myers Squibb Company; Zenith Laboratories ST: New York IN: MTC SU:


PS -- NY110 -- 2132 07/22/92 17:01 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 22, 1992
Words:145
Previous Article:RUSSIA APPROVES FIST ONCE-A-DAY QUINOLONE FOR ANTI-INFECTIVE USE
Next Article:DATASOUTH COMPUTER CORPORATION ANNOUNCES EARNINGS
Topics:


Related Articles
BRISTOL-MYERS SQUIBB ANNOUNCES AGREEMENT WITH SCHERING AG
BRISTOL-MYERS SQUIBB COMPANY WINS INJUNCTION FOR EXCEDRIN PM AGAINST TYLENOL PM
BRISTOL-MYERS SQUIBB COMPANY ISSUES STATEMENT
BRISTOL-MYERS SQUIBB COMPANY WINS APPEAL ON BUSPAR(R) PATENT INFRINGEMENT LAWSUIT
BRISTOL-MYERS SQUIBB FILES CLAIMS AGAINST CANADIAN COMPANY FOR MISREPRESENTATION OF ANTICANCER PRODUCT
ROYCE LABORATORIES, INC. ANNOUNCES RECEIPT OF COURT ORDER ON ITS MOTION TO SET ASIDE INJUNCTION AND DISMISS COMPLAINT
ROYCE LABORATORIES, INC. FILES PETITION SEEKING REVIEW OF FDA DECISION TO DELAY APPROVAL OF ABBREVIATED NEW DRUG APPLICATION FOR CAPTOPRIL PENDING...
Bristol-Myers Squibb Taxol(R) Data Exclusivity in Europe Upheld by Dutch Court
Consumer Groups File Class Actions Against Bristol-Myers Squibb.
Thai AIDS activists score victory over pharmaceutical giant; court strikes down exclusive patent; government to offer cheaper generic drug. (World).

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters